Malignant Lung Neoplasm

A 26 year old non-smoker was diagnosed with lung adenocarcinoma and underwent thoracoscopic resection and treatment with cisplatin and pemetrexed. Panel NGS sequencing of the surgical sample detected … (full text at CIViC)

PMID 31064887 · Guan et al., 2019 · Open in CIViC

Case report of a 30-year-old male with lung adenocarcinoma and metastasis to several organs, including several lesions in the brain. NGS assay (Foundation One CDX panel) detected the EGRF::RAD51 fusio… (full text at CIViC)

PMID 35245845 · Copia Sperandio et al., 2022 · Open in CIViC

This is a case report of a 45-year-old male never smoker that was diagnosed with metastatic lung adenocarcinoma. The patient responded poorly to the initial chemoimmunotherapy (carboplatin, pemetrexed… (full text at CIViC)

PMID 38525318 · Lai et al., 2024 · Open in CIViC

In a cohort of NSCLC patients treated with tyrosine kinase inhibitors erlotinib or gefitinib, 61 patients with uncommon mutations of unknown clinical significance (UMUCS) in EGFR exons 18-21 responded… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a cohort of NSCLC patients tested for mutation in EGFR exons 18-21 a subset had uncommon mutations of unknown clinical significance (UMUCS). The most commonly occurring UMUCS were G719 and L861 mut… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had p… (full text at CIViC)

PMID 27022112 · Urata et al., 2016 · Open in CIViC

194 somatic mutations seen in primary lung cancers were functionally evaluated using three approaches: (1) differences in pattern or extent of changes in gene expression in A549 cells induced by trans… (full text at CIViC)

PMID 27478040 · Berger et al., 2016 · Open in CIViC

Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor su… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC)

PMID 19671843 · Jackman et al., 2009 · Open in CIViC

In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR S768_D770insSVD mutation was associated with resistance to erlotinib treatment. The patient su… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, two patients with the EGFR exon 20 insertion S768_D770dup received osimertinib treatment. A 59 year old f… (full text at CIViC)

PMID 31208370 · Fang et al., 2019 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor sam… (full text at CIViC)

PMID 25521405 · Hellmann et al., 2014 · Open in CIViC

S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treate… (full text at CIViC)

PMID 27211795 · Leventakos et al., 2016 · Open in CIViC

In a phase 2 trial, 129 patients with lung adenocarcinoma with EGFR mutations including mutations other than exon 19 deletions or exon 21 L858R substitutions who had no more than one previous chemothe… (full text at CIViC)

PMID 22452895 · Yang et al., 2012 · Open in CIViC

The S768N mutation was first reported in a cohort of African American patients with non-small cell lung cancer (NSCLC). Classical EGFR mutations such as the L858R mutation and exon 19 deletions, foun… (full text at CIViC)

PMID 19786660 · Leidner et al., 2009 · Open in CIViC

Cells expressing EGFR harboring the S768N mutation were resistant to erlotinib treatment of up to 3uM, as measured using an in vitro fibril formation assay. This contrasts with cells expressing the L8… (full text at CIViC)

PMID 21132006 · Harada et al., 2011 · Open in CIViC

In a pulmonary undifferentiated non-small cell lung cancer patient harboring EGFR S784F mutation, EGFR S784F was reported to be resistant to erlotinib treatment. The patient was initially treated with… (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have S784F mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

A case report of a 56 year old male with metastatic lung adenocarcinoma to the leptomeninges, in whom two rare EGFR::SEPT14 fusions were identified. On second recurrence, NGS was performed on the CSF,… (full text at CIViC)

PMID 34486539 · Zheng et al., 2022 · Open in CIViC

Case report of a 62-year-old woman with lung adenocarcinoma. She underwent treatment with liposome-paclitaxel and carboplatin. They detected EGFR-SEPT14 fusion (N-terminal amino acids of EGFR and C-te… (full text at CIViC)

PMID 31345345 · Zhu et al., 2019 · Open in CIViC

This article identified in-frame EGFR-SHC1 fusions in a 61-year-old male smoker with stage IIIA NSCLC, retaining functional kinase domains. RNA-based NGS fusion assays was used for detecting actionabl… (full text at CIViC)

PMID 31382039 · Pan et al., 2019 · Open in CIViC

In this study, the authors employed next-generation sequencing (NGS) to compare the genetic profiles of lung adenocarcinoma (LUAD) patients with and without adrenal metastases. An EGFR-SUMF2 fusion wa… (full text at CIViC)

PMID 39673828 · Pan et al., 2025 · Open in CIViC

T725M and L861R are rare cancer-associated mutations and increase EGFR activity in the absence of the activating EGF ligand in cell-based assays

PMID 24743239 · U et al., 2014 · Open in CIViC

In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation.

PMID 24623981 · Ding et al., 2014 · Open in CIViC

Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.

PMID 24729716 · Li et al., 2014 · Open in CIViC